News
-
-
PRESS RELEASE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH issued an update on Formycon AG, maintaining a Buy recommendation and reducing the target price to €50. Recent positive developments drive optimism for Formycon's sales of Keytruda biosimilar FYB206 -
-
-
-
PRESS RELEASE
Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026
Formycon reports positive operational progress and strong revenue growth in the first quarter of 2026. Achievements in biosimilar portfolio and strategic roadmap. Financial figures and guidance confirmed -
-
PRESS RELEASE
Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
Formycon AG invites to conference call on Q1 2026 results and announces participation in investor conferences. Key focus on biosimilars and financial outlook -
-
PRESS RELEASE
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union
Formycon expands commercial portfolio with the launch of Aflibercept biosimilars Ahzantive(R) and Baiama(R) in the European Union, reinforcing market penetration and growth strategy
